Table 2.
Growth Data and Biomarkers of Study Subjects by Their DAAB Status
| Variable | DAAB+ (n=14) | DAAB− (n=205) | P value |
|---|---|---|---|
| Age, yr | 8.7±0.2 | 8.8±0.4 | 0.05 |
| Height SDS | 1.06±0.84 | 0.69±1.28 | 0.31 |
| Corrected height SDS | 0.31±1.18 | 0.07±0.87 | 0.47 |
| BMI SDS | 0.65 (−0.29 to 1.27) | 0.3 (−0.36 to 1.16) | 0.83 |
| Weight SDS | 0.87 (0.21 to 1.13) | 0.66 (0.1 to 1.43) | 0.58 |
| Overweight, % | 28.6 | 20 | 0.49 |
| Obese, % | 14.3 | 10.2 | 0.65 |
| IGF-1, μg/L | 139.4±38.5 | 156.5±41.9 | 0.13 |
| IGFBP-3, μg/mL | 3.94±0.86 | 4.2±0.79 | 0.29 |
| IGF-1/IGFBP-3 molar ratio | 0.195±0.028 | 0.206±0.038 | 0.19 |
| Δ Height SDS | 0.23±0.99 (n=13) | 0.17±0.84 (n=189) | 0.81 |
| Δ BMI SDS | −0.48 (−1.44 to 0.36) (n=13) | −0.22 (−1.06 to 0.62) (n=189) | 0.48 |
Values are expressed as mean±1 standard deviation (SD) or median (interquartile range).
DAAB, diabetes-associated antibodies; SDS, standard deviation score; BMI, body mass index; IGF-1, insulin-like growth factor 1; IGFBP-3, insulin-like growth factor binding protein 3; Δ, change between the present age and 18 months of age.